Eclipse trial e nsure s vas c ular c l osure dev i ce s p eed s h e mostasis
This presentation is the property of its rightful owner.
Sponsored Links
1 / 8

ECLIPSE Trial: E nsure’s Vas c ular C l osure Dev i ce S p eed s H e mostasis PowerPoint PPT Presentation


  • 80 Views
  • Uploaded on
  • Presentation posted in: General

ECLIPSE Trial: E nsure’s Vas c ular C l osure Dev i ce S p eed s H e mostasis. S. Chiu Wong MD Director, Cardiac Catheterization Laboratories New York Presbyterian Hosp.- Cornell Campus Professor of Medicine Weill Medical College of Cornell University.

Download Presentation

ECLIPSE Trial: E nsure’s Vas c ular C l osure Dev i ce S p eed s H e mostasis

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Eclipse trial e nsure s vas c ular c l osure dev i ce s p eed s h e mostasis

ECLIPSE Trial: Ensure’s Vascular Closure Device Speeds Hemostasis

S. Chiu Wong MD

Director, Cardiac Catheterization Laboratories

New York Presbyterian Hosp.- Cornell Campus

Professor of Medicine

Weill Medical College of Cornell University

SCAI / ACCi2 2008 Late Breaking TrialApril 2nd Chicago, IL


Eclipse trial eclipse closure device

ECLIPSE TrialEclipse® Closure Device

  • The investigational ExoSeal device (Cordis, Miami FL) is a novel 3rd generation 6 Fr. extra-vascular closure device with a painless deployment mechanism that delivers a poly-glycolic acid (PGA) “felt-like” plug atop the femoral artery anchored by the neuro-vascular bundle sheath.


Eclipse trial eclipse trial design

ECLIPSE Trial ECLIPSE Trial Design

  • U.S. multicenter pivotal study comparing ExoSeal and manual compression with 2:1 randomization was performed to assess the safety and efficacy of ExoSeal in patients undergoing 6Fr. diagnostic and interventional coronary/peripheral procedures


Eclipse trial e nsure s vas c ular c l osure dev i ce s p eed s h e mostasis

ECLIPSE Trial Objectives

  • Two primary effectiveness endpoints to be tested for superiority:

    • Time to hemostasis (TTH)

    • Time to ambulation (TTA)

  • Primary safety endpoint to be tested for non-inferiority:

    • 30-day combined rate of access site related complications including bleeding, infection, ischemia or injury requiring medical or surgical treatment


Eclipse trial e nsure s vas c ular c l osure dev i ce s p eed s h e mostasis

ECLIPSE Trial Patient Enrollment

ExoSeal® 6F VCD (17 U.S. Sites)N = 488

Roll-in N = 87

Withdrawn N = 5 (2.7%)

Randomized N = 401

30 day FU N = 82 (94.3%)

ExoSeal® (N=267)

Mannual Compression (n=134)

Withdrawn N = 14 (5.2%)

Withdrawn N = 10 (7.5%)

30-day FU N=253 ( 94.8%)

30-day FU N=124 (92.5%)


Eclipse trial e nsure s vas c ular c l osure dev i ce s p eed s h e mostasis

ECLIPSE Trial Results: Primary Effectiveness Endpoints


Eclipse trial e nsure s vas c ular c l osure dev i ce s p eed s h e mostasis

ECLIPSE Trial Results: Primary 30-Day Safety Endpoints

zero!


Eclipse trial e nsure s vas c ular c l osure dev i ce s p eed s h e mostasis

ECLIPSE Trial Conclusions

  • In this multi-center randomized trial in pts following 6 Fr. diagnostic/interventional procedures, a significant reduction in the TTH and TTA (primary effectiveness endpoints) was achieved in pts treated with the investigational ExoSeal device compared with MC

  • Device deployment was achieved promptly in about 1 minute on average following procedure

  • There was no difference in procedural success rates in both the ExoSeal® and MC groups

  • Remarkably, there were no30-day combined access site related complications (primary safety endpoint) reported in either treatment cohort

  • Exoseal is non-inferior to MC in composite major adverse event at the pre-specified 4% margin level

  • Exoseal®compares favorably to manual compression for arteriotomy site management post 6 Fr. invasive/interventional procedures.


  • Login